Etiology and Pathophysiology of Ovarian Cancer —Ovarian cancers are classified into epithelial, stromal, or germ cell cancers based on their putative cell of origin.

Biomarkers of Response to Epidermal Growth Factor Receptor Inhibitors in Non–Small-Cell Lung Cancer Working Group: Standardization for Use in the Clinical Trial Setting Ovarian carcinogenesis, as in ...

A recent study published in Genes & Diseases reveals a novel role of XPR1 in promoting ovarian cancer growth by regulating ...

Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer-shifting the paradigm. Hum Pathol 2011; 42 :918–931. Article CAS PubMed Google Scholar ...

In the case of human ovarian cancer, this laboratory (Amer. J. Physiol. 296:R1716-1725, 2009) previously found that the OGF-OGFr axis is present and functional in human ovarian cancer.

A pairing of two experimental drugs inhibits tumor growth and blocks drug-induced resistance in ovarian cancer, according to ...

Discovery of a subset of high-risk progenitor cells that reside in fallopian tube supportive tissue, or stroma, could pave the way for better approaches to prevent and detect high-grade serous ...

Despite considerable efforts to improve early detection, and advances in chemotherapy, metastasis remains a major challenge in the clinical management of ovarian cancer. Studies of new murine ...

Merck’s Keytruda, with more than 40 approved indications, hasn’t yet been able to crack specifically into ovarian cancer. But with promising early results from a phase 3 study in certain ...

Perhaps PD-1 inhibitors just aren’t for ovarian cancer after all. | Merck's and GSK's similar overall survival setbacks suggest that PD-1 inhibitors may not be for ovarian cancer after all.

The Pathogenesis of the Ovarian Hyperstimulation Syndrome. Author: Ursula Brigitte Kaiser, M.D. Author Info & Affiliations. Published August 21, 2003. N Engl J Med 2003; 349: 729-732.

Biomarkers of Response to Epidermal Growth Factor Receptor Inhibitors in Non–Small-Cell Lung Cancer Working Group: Standardization for Use in the Clinical Trial Setting Ovarian carcinogenesis, as in ...